As you might know, Travere Therapeutics, Inc. (NASDAQ:TVTX) just kicked off its latest quarterly results with some very strong numbers. Revenues beat expectations coming in atUS$82m, ahead of estimates by 6.3%. Statutory losses were somewhat smaller thanthe analysts expected, coming in at US$0.47 per share. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Travere Therapeutics after the latest results.

We've discovered 1 warning sign about Travere Therapeutics. View them for free.NasdaqGM:TVTX Earnings and Revenue Growth May 4th 2025

After the latest results, the 15 analysts covering Travere Therapeutics are now predicting revenues of US$397.5m in 2025. If met, this would reflect a huge 45% improvement in revenue compared to the last 12 months. Losses are predicted to fall substantially, shrinking 59% to US$1.04. Before this earnings announcement, the analysts had been modelling revenues of US$385.6m and losses of US$1.43 per share in 2025. So it seems there's been a definite increase in optimism about Travere Therapeutics' future following the latest consensus numbers, with a very favorable reduction to the loss per share forecasts in particular.

See our latest analysis for Travere Therapeutics

Despite these upgrades,the analysts have not made any major changes to their price target of US$33.73, implying that their latest estimates don't have a long term impact on what they think the stock is worth. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. There are some variant perceptions on Travere Therapeutics, with the most bullish analyst valuing it at US$47.00 and the most bearish at US$22.00 per share. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Travere Therapeutics' past performance and to peers in the same industry. For example, we noticed that Travere Therapeutics' rate of growth is expected to accelerate meaningfully, with revenues forecast to exhibit 65% growth to the end of 2025 on an annualised basis. That is well above its historical decline of 0.1% a year over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in the industry are forecast to see their revenue grow 18% per year. So it looks like Travere Therapeutics is expected to grow faster than its competitors, at least for a while.

Story Continues

The Bottom Line

The most important thing to take away is that the analysts reconfirmed their loss per share estimates for next year. Happily, they also upgraded their revenue estimates, and are forecasting them to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have estimates - from multiple Travere Therapeutics analysts - going out to 2027, and you can see them free on our platform here.

Before you take the next step you should know about the 1 warning sign for Travere Therapeutics that we have uncovered.

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

View Comments